385 related articles for article (PubMed ID: 30309389)
1. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
Scheltens P; Hallikainen M; Grimmer T; Duning T; Gouw AA; Teunissen CE; Wink AM; Maruff P; Harrison J; van Baal CM; Bruins S; Lues I; Prins ND
Alzheimers Res Ther; 2018 Oct; 10(1):107. PubMed ID: 30309389
[TBL] [Abstract][Full Text] [Related]
2. Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy.
Hoffmann T; Meyer A; Heiser U; Kurat S; Böhme L; Kleinschmidt M; Bühring KU; Hutter-Paier B; Farcher M; Demuth HU; Lues I; Schilling S
J Pharmacol Exp Ther; 2017 Jul; 362(1):119-130. PubMed ID: 28446518
[TBL] [Abstract][Full Text] [Related]
3. In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease.
Briels CT; Stam CJ; Scheltens P; Bruins S; Lues I; Gouw AA
Clin Neurophysiol; 2020 Jan; 131(1):88-95. PubMed ID: 31759193
[TBL] [Abstract][Full Text] [Related]
4. Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD.
Vijverberg EGB; Axelsen TM; Bihlet AR; Henriksen K; Weber F; Fuchs K; Harrison JE; Kühn-Wache K; Alexandersen P; Prins ND; Scheltens P
Alzheimers Res Ther; 2021 Aug; 13(1):142. PubMed ID: 34425883
[TBL] [Abstract][Full Text] [Related]
5. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects.
Lues I; Weber F; Meyer A; Bühring U; Hoffmann T; Kühn-Wache K; Manhart S; Heiser U; Pokorny R; Chiesa J; Glund K
Alzheimers Dement (N Y); 2015 Nov; 1(3):182-195. PubMed ID: 29854937
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
8. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
9. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
10. Exploring the binding mode of PQ912 against secretory glutaminyl cyclase through systematic exploitation of conformational ensembles.
Chandran R; Dileep KV
Chem Biol Drug Des; 2021 Nov; 98(5):850-856. PubMed ID: 34423556
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
[TBL] [Abstract][Full Text] [Related]
12. Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam).
Feldman HH; Luchsinger JA; Léger GC; Taylor C; Jacobs DM; Salmon DP; Edland SD; Messer K; Revta C; Flowers SA; Jones KS; Koulman A; Yarasheski KE; Verghese PB; Venkatesh V; Zetterberg H; Durant J; Lupo JL; Gibson GE;
PLoS One; 2024; 19(5):e0302998. PubMed ID: 38809849
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P;
Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875
[TBL] [Abstract][Full Text] [Related]
14. Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial.
Decourt B; Drumm-Gurnee D; Wilson J; Jacobson S; Belden C; Sirrel S; Ahmadi M; Shill H; Powell J; Walker A; Gonzales A; Macias M; Sabbagh MN
Curr Alzheimer Res; 2017; 14(4):403-411. PubMed ID: 28124585
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
Grove RA; Harrington CM; Mahler A; Beresford I; Maruff P; Lowy MT; Nicholls AP; Boardley RL; Berges AC; Nathan PJ; Horrigan JP
Curr Alzheimer Res; 2014 Jan; 11(1):47-58. PubMed ID: 24359500
[TBL] [Abstract][Full Text] [Related]
16. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease.
van Dyck CH; Mecca AP; O'Dell RS; Bartlett HH; Diepenbrock NG; Huang Y; Hamby ME; Grundman M; Catalano SM; Caggiano AO; Carson RE
Alzheimers Res Ther; 2024 Jan; 16(1):20. PubMed ID: 38273408
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
Burns DK; Alexander RC; Welsh-Bohmer KA; Culp M; Chiang C; O'Neil J; Evans RM; Harrigan P; Plassman BL; Burke JR; Wu J; Lutz MW; Haneline S; Schwarz AJ; Schneider LS; Yaffe K; Saunders AM; Ratti E;
Lancet Neurol; 2021 Jul; 20(7):537-547. PubMed ID: 34146512
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.
Winblad B; Andreasen N; Minthon L; Floesser A; Imbert G; Dumortier T; Maguire RP; Blennow K; Lundmark J; Staufenbiel M; Orgogozo JM; Graf A
Lancet Neurol; 2012 Jul; 11(7):597-604. PubMed ID: 22677258
[TBL] [Abstract][Full Text] [Related]
19. Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.
Tsai RM; Miller Z; Koestler M; Rojas JC; Ljubenkov PA; Rosen HJ; Rabinovici GD; Fagan AM; Cobigo Y; Brown JA; Jung JI; Hare E; Geldmacher DS; Natelson-Love M; McKinley EC; Luong PN; Chuu EL; Powers R; Mumford P; Wolf A; Wang P; Shamloo M; Miller BL; Roberson ED; Boxer AL
JAMA Neurol; 2020 Feb; 77(2):215-224. PubMed ID: 31710340
[TBL] [Abstract][Full Text] [Related]
20. A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease.
Malpas CB; Vivash L; Genc S; Saling MM; Desmond P; Steward C; Hicks RJ; Callahan J; Brodtmann A; Collins S; Macfarlane S; Corcoran NM; Hovens CM; Velakoulis D; O'Brien TJ
J Alzheimers Dis; 2016 Jul; 54(1):223-32. PubMed ID: 27447428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
